Text/ Zhao Tianyu
Photo / Produced by the Finance & Economics Health team
Editor / Wang Xiao
Photo/pixabay
After two years of the new crown epidemic, more than 400 A-share health companies have risen sharply in the early days of the new crown epidemic, but throughout 2021, the trend has gradually diverged, with ups and downs, testing investors' confidence and patience in the ups and downs.
In 2021, 7 of the top 100 A-share companies are from the health field, 3 less than in 2020, of which BeiGene entered the top 100 in market capitalization after listing at the end of 2021, while Changchun High-tech, Yunnan Baiyao, Tigermed and Fosun Pharma fell out of the top 100 companies.
In Vanity Fair, the top seats have also changed: at the end of 2020, the highest market capitalization in the health sector is Hengrui Pharmaceutical (600276. SH); by the end of 2021, it will be Mindray Medical (300760. SZ）。
Specific to the rise and fall performance of companies in the health field in 2021, "Finance and Economics" refers to the Shenyin Wanguo industry classification, more than 400 listed companies related to medical and pharmaceutical in A-shares, and the largest increase in 2021 is Jiuan Medical (002432. SZ), up 441 percent; the biggest drop was 300869. SZ), down 66% for the year.
